Why Vaxcyte, Inc.’s (PCVX) Stock Is Down 5.74%
As of Wednesday, July 08, Vaxcyte, Inc.’s PCVX share price has dipped by 5.74%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Commentary & Analysis
Why Vaxcyte, Inc.’s (PCVX) Stock Is Up 5.28%
As of Friday, June 26, Vaxcyte, Inc.’s PCVX share price has surged by 5.28%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Vaxcyte, Inc.’s (PCVX) Stock Is Down 5.59%
As of Monday, May 18, Vaxcyte, Inc.’s PCVX share price has dipped by 5.59%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Vaxcyte, Inc.’s (PCVX) Stock Is Down 9.79%
As of Thursday, May 07, Vaxcyte, Inc.’s PCVX share price has dipped by 9.79%, which has investors questioning if this is right time to buy.Michael Rose
Why Vaxcyte, Inc.’s (PCVX) Stock Is Down 10.28%
As of Thursday, May 07, Vaxcyte, Inc.’s PCVX share price has dipped by 10.28%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | PCVX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9,318.2 | $292.6 | 76% |
|
| Shares Out (Mil) | 144.5 | 54.4 | 70% |
|
| Institutional Ownership | 99.5% | 93.2% | 89% |
|
| Float (Mil) | 136.5 | 40.2 | 67% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 915 | 544 | 69% |
|
| Price Change (52-week) |
100.3% | 59.7% | 90% |
|
| Growth | PCVX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (53.8%) | (10.1%) | 6% |
|
| EPS (5yr) | (13.3%) | 16.0% | 20 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (16.5%) | (15.6%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($2.139) | ($8.197) | ($7.217) | |
| Month Ago EPS | ($2.164) | ($8.483) | ($7.421) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($2.164) | ($8.483) | ($7.421) | |
| Year/Year Chg | 8.7% | 45.5% | 7.3% | |
| Financials | PCVX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($1,064) | ($43) | 1% |
|
| EPS (TTM) | ($7.647) | ($1.400) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($881) | ($31) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($123) | $2 | 13% |
|
| Long-Term Debt (Q1) (Mil) | $109 | $4 | 45% |
|
| Enterprise Value (Q1) (Mil) | na | $164 | na |
|
| Valuation | PCVX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.29 | 2.83 | 67% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PCVX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (33.0%) | (47.5%) | 16% |
|
| ROE | (36.5%) | (55.0%) | 18% |
|
| Liabilities to Assets | 12.1% | 29.6% | 7% |
|
| F-Score | 2 | 3 | 7% |
|
Vaxcyte, Inc. did not pass any screens on 8/21/2026.
